Home Crinecerfont
2025

Crinecerfont

by cyb2025
R. Souza
Crinecerfont

RODRIGO SOUZA
Biocatalysis and Organic Synthesis Group, Chemistry Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Crinecerfont is an orally administered, nonsteroidal corticotropinreleasing factor type 1 (CRF1) receptor antagonista, sold under the brand name Crenessity, approved for medical use by the FDA in December 2024 for the treatment of classic congenital adrenal hyperplasia (CAH). By selectively inhibiting CRF1, Crinecerfont reduces excessive adrenocorticotropic hormone (ACTH) drive and lower the overproduction of adrenal androgens that is characteristic of CAH and it considers to be a first-in-class medicine.

 

 

ABOUT THE AUTHOR

Rodrigo Souza – Since I started my independent career, I have pursuit the development of new technologies to guide research by innovative ideas. We have been working at Federal University of Rio de Janeiro on the establishment of continuous flow technology for active pharmaceutical ingredients (API) synthesis in Brazil, showing that is possible to reduce costs on production allowing the reduction of the final price of the medicine.

Latest issue

September / October 2025

View Issue

Archive

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt!

Chemistry Today - Archive
Go to archive

Content from magazine

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores.
View all content

The most read

@2019 - All Right Reserved. Designed and Developed by PenciDesign

Login